+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn

+ Translate
+ Recently Requested

Erythropoietin response to anaemia is not altered by surgery or recombinant human erythropoietin therapy



Erythropoietin response to anaemia is not altered by surgery or recombinant human erythropoietin therapy



British Journal Of Haematology. 87(4): 695-699



Recombinant human erythropoietin (EPO) therapy has been shown to increase red blood cell (RBC) production and facilitate autologous blood donation before elective surgery. However, recent reports have suggested that surgery and/or EPO therapy may suppress endogenous erythropoietin secretion in response to anaemia. We therefore analysed the haemoglobin/erythropoietin relationship preoperatively and postoperatively in 71 autologous blood donors subjected to aggressive phlebotomy and six treatments with either EPO (150 U/kg, n = 16, 300 U/kg, n = 18, or 600 U/kg, n = 19) or placebo (n = 18). Using data from the three preoperative study visits, the linear relationship between log erythropoietin and haemoglobin was determined for each of the 18 placebo patients. We found no significant differences in the slopes of the relationships in this group during aggressive phlebotomy. Furthermore, there was no evidence of a significant difference in the erythropoietin level recorded postoperatively for each patient to that predicted from the patient's postoperative haemoglobin level, based on the haemoglobin/ log erythropoietin relationship preoperatively. Similarly, for each of the EPO-treated groups, there was no evidence of a significant difference when comparing the recorded erythropoietin level to that predicted from each patient's postoperative haemoglobin level, based on the haemoglobin/log erythropoietin relationship preoperatively. We conclude that preoperative recombinant human erythropoietin therapy and/or surgery do not adversely affect the postoperative erythropoietin response to anaemia.

(PDF emailed within 0-6 h: $19.90)

Accession: 008621959

Download citation: RISBibTeXText

PMID: 7986708

DOI: 10.1111/j.1365-2141.1994.tb06725.x



Related references

Therapeutic effect of recombinant human erythropoietin on anaemia with erythropoietin deficiency in diabetic patients. Diabetic Medicine 20(8): 661-664, 2003

Recombinant human erythropoietin may correct erythropoietin-deficient hyporegenerative anaemia in children given cardiac transplantation. British Journal of Haematology 88(3): 623-625, 1994

Recombinant human erythropoietin is effective in correcting erythropoietin-deficient anaemia after allogeneic bone marrow transplantation. British Journal of Haematology 80(4): 545-549, 1992

Ratio of baseline erythropoietin level and corrected reticulocyte count as an indicator for a favourable response to recombinant human erythropoietin therapy in anaemic cancer patients. Journal of Clinical Laboratory Analysis 15(5): 260-266, 2001

Ratio of baseline erythropoietin (EPO) level and corrected reticulocyte count as an indicator for a favourable response to recombinant human erythropoietin (rhEPO) therapy in anaemic cancer patients. Journal of Clinical Laboratory Analysis 15(5): 260-266, 2001

Recombinant Human Erythropoietin Increases lnterleukin-1β Production in Cultured Peripheral Blood Mononuclear Cells from Patients Resistant to Recombinant Human Erythropoietin Therapy. Nephron 67(2): 245-247, 1994

Recombinant human erythropoietin increases interleukin-1 beta production in cultured peripheral blood mononuclear cells from patients resistant to recombinant human erythropoietin therapy. Nephron 67(2): 245-247, 1994

Prediction of response to treatment with recombinant human erythropoietin in anaemia associated with cancer. Medical Oncology 15 Suppl 1: S38-S46, 1998

Erythropoiesis after therapy with recombinant human erythropoietin: a dose-response study in anemic cancer surgery patients. Vox Sanguinis 76(1): 38-42, 1999

Effects of azathioprine on response of renal anaemia to subcutaneous recombinant human erythropoietin. Journal of Clinical Pathology 46(1): 41-44, 1993

Response of anaemia in rheumatoid arthritis to treatment with subcutaneous recombinant human erythropoietin. Annals of the Rheumatic Diseases 51(6): 747-752, 1992

Erythropoietin deficiency: a complication of cisplatin therapy and its treatment with recombinant human erythropoietin. American Journal of Pediatric Hematology/Oncology 13(4): 426-430, 1991

Effective therapy of aplastic anaemia post-hepatitis with recombinant human erythropoietin. American Journal of Hematology 46(1): 59-60, 1994

Recombinant human erythropoietin therapy in patients with cancer-related anaemia What have we learned?. Medical Oncology (Basingstoke) 15(SUPPL 1): S47-S49, 1998

Evaluation of erythroid marrow response to recombinant human erythropoietin in patients with cancer anaemia. Haematologica 77(6): 494-501, 1992